Most recently, a large UK Biobank analysis found no increase in BC incidence among carriers of pathogenic MLH1, MSH2, MSH6, or PMS2 variants [159], arguing against classifying BC as part of the LS tumor spectrum. Here, MSH6 is linked to neoplasm.